Filter your results
- 4
- 4
- 4
- 4
- 4
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 4
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
|
|
sorted by
|
|
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNsScience Immunology, 2022, ⟨10.1126/sciimmunol.abp8966⟩
Journal articles
hal-03948899v1
|
||
|
Oropharyngeal and intestinal concentrations of opportunistic pathogens are independently associated with death of SARS-CoV-2 critically ill adultsCritical Care, 2022, 26 (1), pp.300. ⟨10.1186/s13054-022-04164-0⟩
Journal articles
pasteur-04098000v1
|
||
|
Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2Journal of Experimental Medicine, 2022, 219 (7), pp.e20220638. ⟨10.1084/jem.20220638⟩
Journal articles
hal-03697587v1
|
||
|
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodiesProceedings of the National Academy of Sciences of the United States of America, 2022, 119 (21), pp.349-363. ⟨10.1073/pnas.2200413119⟩
Journal articles
hal-03856619v2
|